Physician profile
Charles Halasz
NPI 1538137450
$25,749.04
in general payments reported to CMS, 2019-2025
43 companies · $4,709 in 2025
The $4,709 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,981 · 2020: $2,357 · 2021: $3,070 · 2022: $3,728 · 2023: $4,478 · 2024: $4,427 · 2025: $4,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,000 · Education: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,913.95 |
| Consulting Fee | $1,000.00 |
| Education | $699.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,806.80 | 2019-2025 | |
| Janssen Biotech, INC. | $2,335.08 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $2,054.02 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,752.55 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $1,588.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,545.38 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,184.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,137.50 | 2019-2025 | |
| The Daavlin Distributing Co | $1,000.00 | 2025 | Phothera Phototherapy Devices |
| Incyte Corporation | $976.81 | 2021-2025 | Opzelura |
| Pfizer INC. | $926.76 | 2019-2025 | |
| Leo Pharma INC. | $814.09 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $772.94 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $645.18 | 2023-2025 | Zoryve |
| Amgen INC. | $629.44 | 2019-2025 | Otezla, Otezla, Enbrel |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Halasz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.